When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients.

Aging brings changes we can see, like wrinkles and slower movement. It also brings quieter shifts — like lighter sleep or waking up more often at night. One issue many older adults experience — but ...

Add Yahoo as a preferred source to see more of our stories on Google. You’re driving somewhere, eyes on the road, when you start to feel a tingling sensation in your lower abdomen. That extra-large ...